Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS) announced an investor conference call and webcast on January 8, 2026 at 4:30 PM ET to present an interim clinical update from CORAL-1, its multi-center Phase 1 dose-escalation study of KB407 in patients with cystic fibrosis. The update will focus on data from the highest dose cohort and include molecular assessments of KB407 transduction and wild-type CFTR protein expression following inhaled administration.

Live webcast access is provided and an archived recording will be available on the company’s Investors website for at least 30 days.

News Market Reaction – KRYS

+1.03%

2 alerts

+1.03% Session close to close

+3.0% Peak Tracked

$7.14B Market Cap

1.2x Rel. Volume

In the Jan 8 session, KRYS gained 1.03%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets expectations for an interim readout from the highest-dose cohort of the Phase...

Analysis

This announcement sets expectations for an interim readout from the highest-dose cohort of the Phase 1 CORAL-1 study of KB407 in cystic fibrosis, with an investor call on January 8, 2026. It continues Krystal’s pattern of regularly updating on pipeline trials alongside solid commercial performance. Investors will likely focus on molecular evidence of CFTR expression and safety signals, comparing this early CF program to prior ophthalmology and aesthetic trial milestones.

Key Figures

Phase: Phase 1 Dose cohort: Highest dose cohort Investor call time: 4:30 pm ET +5 more

8 metrics

Phase Phase 1 CORAL-1 study of KB407 in cystic fibrosis

Dose cohort Highest dose cohort Focus of CORAL-1 interim clinical update

Investor call time 4:30 pm ET January 8, 2026 KB407 interim data call

Share price $249.39 Price prior to KB407 interim update announcement

52-week range $122.80–$265.915 KRYS 52-week low and high pre-announcement

Market cap $7,095,982,874 Equity value before KB407 interim update

Daily move 1.91% Price change on the day of the announcement

Volume multiple 1.35x Today’s volume vs 20-day average before data call

Historical Context

5 past events · Latest: Jan 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 05	Conference appearance	Neutral	-0.9%	Announcement of J.P. Morgan Healthcare Conference presentation and webcast details.
Nov 26	Conference appearance	Neutral	+0.8%	Evercore Healthcare Conference participation and investor meetings disclosure.
Nov 03	Earnings results	Positive	+0.2%	Strong Q3 2025 VYJUVEK revenue, high margins, and solid cash position.
Oct 21	Earnings preview	Neutral	-2.6%	Scheduling of Q3 2025 results release and related investor call.
Oct 14	Regulatory designation	Positive	+1.8%	FDA platform technology designation for the HSV-1 vector used in KB801.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news — earnings, FDA designations, and conference updates — has generally seen modest, directionally aligned price reactions without sharp divergences.

Recent Company History

Over the past six months, KRYS has balanced commercial progress with pipeline development. Earnings on Nov 3, 2025 highlighted strong VYJUVEK revenue and profitability, followed by an FDA platform technology designation for KB801 on Oct 14, 2025. Multiple conference announcements (Evercore, J.P. Morgan) underscored active investor engagement. The current KB407 Phase 1 interim update fits this pattern of steady clinical and commercial communication supporting the broader gene-therapy pipeline.

Key Terms

phase 1, cystic fibrosis, transduction, cystic fibrosis transmembrane conductance regulator (CFTR) protein

4 terms

phase 1 medical

"multi-center, dose escalation Phase 1 study evaluating KB407 in patients"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

cystic fibrosis medical

"Phase 1 study evaluating KB407 in patients with cystic fibrosis."

A genetic disease that causes the body to produce thick, sticky mucus that clogs airways and digestive passages, leading to ongoing lung infections, breathing difficulty, and problems absorbing nutrients. For investors, cystic fibrosis matters because treatments range from symptom management to pricey, targeted drugs that can change patient outcomes; progress in therapies, clinical trial results, regulatory approvals, and reimbursement decisions can significantly affect the commercial value of companies working in this area.

transduction medical

"include molecular assessments of KB407 transduction and wild-type cystic"

Transduction is the process by which genetic instructions are delivered into a cell using a carrier, often a harmless virus, so the cell can read and act on those instructions. For investors, transduction is central to many gene and cell therapies because it determines how effectively and safely a treatment reaches target cells—affecting clinical success, manufacturing complexity, regulatory review, and commercial viability, much like the reliability of a delivery service impacts product performance.

cystic fibrosis transmembrane conductance regulator (CFTR) protein medical

"wild-type cystic fibrosis transmembrane conductance regulator (CFTR) protein expression"

A protein that functions like a tiny faucet on cell surfaces, controlling the flow of salt and water in and out of many tissues; when the CFTR protein doesn't work properly because of genetic mutations, thick mucus and organ damage can result. For investors, CFTR is a clear drug-development and diagnostic target: therapies that restore or compensate for its function can transform patient outcomes and drive meaningful market value in biotech and pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Investor call to be held January 8 at 4:30 pm ET to discuss data update and next steps

PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30 pm ET, to disclose an interim clinical update from CORAL-1, the Company’s multi-center, dose escalation Phase 1 study evaluating KB407 in patients with cystic fibrosis. The interim clinical update will focus on results from patients in the highest dose cohort of CORAL-1 and include molecular assessments of KB407 transduction and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) protein expression following inhaled administration of KB407.

Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53466. For those unable to listen to the live webcast, an archived version will also be available on the Investors section of the Company’s website for at least 30 days.

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK^®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com

FAQ

When will Krystal Biotech (KRYS) present the CORAL-1 interim update?

Krystal Biotech will present the interim CORAL-1 update on January 8, 2026 at 4:30 PM ET via investor call and webcast.

What will Krystal Biotech (KRYS) disclose about KB407 in the CORAL-1 update?

The company will disclose an interim clinical update focused on the highest dose cohort, including molecular assessments of KB407 transduction and wild-type CFTR protein expression.

How can investors access the KRYS live webcast for the CORAL-1 update?

Investors can access the live webcast via the provided webcast link, and an archived recording will be available on the company's Investors website for at least 30 days.

Is the CORAL-1 update a final trial readout for KB407?

No; the announcement describes an interim clinical update from the Phase 1 CORAL-1 study, not a final trial readout or regulatory decision.

Which patient data cohort will be highlighted in Krystal Biotech's CORAL-1 update?

The interim update will highlight results from patients in the highest dose cohort of the CORAL-1 study.